Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Regenxbio (RGNX) Other Gross PP&E Adjustments (2016 - 2025)

Regenxbio has reported Other Gross PP&E Adjustments over the past 11 years, most recently at $144.9 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $144.9 million for Q4 2025, up 6.41% from a year ago — trailing twelve months through Dec 2025 was $144.9 million (up 6.41% YoY), and the annual figure for FY2025 was $144.9 million, up 6.41%.
  • Other Gross PP&E Adjustments for Q4 2025 was $144.9 million at Regenxbio, up from $142.2 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for RGNX hit a ceiling of $144.9 million in Q4 2025 and a floor of $51.3 million in Q1 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was $127.2 million (2023), compared with a mean of $118.7 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 5285.69% in 2021 and later rose 5.05% in 2024.
  • Regenxbio's Other Gross PP&E Adjustments stood at $99.7 million in 2021, then rose by 18.34% to $118.0 million in 2022, then grew by 9.21% to $128.8 million in 2023, then increased by 5.7% to $136.2 million in 2024, then rose by 6.41% to $144.9 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $144.9 million (Q4 2025), $142.2 million (Q3 2025), and $140.6 million (Q2 2025) per Business Quant data.